BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 9169707)

  • 21. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
    Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
    Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
    Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
    Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer.
    Sasaki K; Kawasaki H; Sato M; Koyama K; Yoshimi F; Nagai H
    Dig Surg; 2017; 34(1):60-67. PubMed ID: 27454870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma.
    Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T
    J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
    Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
    Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
    Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
    Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.
    Moog F; Kotzerke J; Reske SN
    J Nucl Med; 1999 Sep; 40(9):1407-13. PubMed ID: 10492357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era.
    Richardson SE; Sudak J; Warbey V; Ramsay A; McNamara CJ
    Leuk Lymphoma; 2012 Mar; 53(3):381-5. PubMed ID: 21877882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.